Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1160 results for pain

  1. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.

  2. Balloon dilatation of pulmonary valve stenosis (IPG67)

    Evidence-based recommendations on balloon dilatation of pulmonary valve stenosis. This involves passing a small deflated balloon up through a blood vessel at the top of the leg and into the blocked area in the heart.

  3. EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

    NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration

  4. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  5. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTE25)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome....

  6. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

  7. Low back pain in adults: early management (CG88)

    This guidance has been updated and replaced by NICE guideline NG59.

  8. Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

  9. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  10. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  11. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults

  12. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

  13. Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.

  14. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  15. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .